Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancer. New Study Reveals How Bladder Cancer “Hijacks” the Immune System — Opening Door to ...

Melanie Stein, ND Clinical improvement in treatment-refractory MCAS with normal conventional biomarkers and profound oral ...

Why do diabetic wounds refuse to heal? A new scientific review highlights how disruptions in the timing and behavior of ...

Chronic diabetic ulcers represent one of the most challenging complications in modern healthcare, affecting over 131 million people worldwide and generating approximately $755 billion in annual ...

Forget hot flashes, exhaustion or night sweats. This pesky, seemingly harmless problem could be a symptom of changing ...

Celldex (NASDAQ:CLDX) announced today that multiple presentations from the Company’s Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU) and ...

With barzolvolimab re-treatment, 62% of patients with ColdU and 60% of patients with SD had a complete response at Week 20 in the OLE. These findings are consistent with the complete response rates in ...

Enrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six ...

AB Science says a newly identified blood biomarker may help assess masitinib activity in its ongoing Phase 3 ALS clinical ...

Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSUTopline data ...

Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients ...